Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06571799 · ClinicalTrials.gov registry record · NA

Study Evaluating the Efficacy and Safety of BENEV Exosome Regenerative Complex+ for Self-perceived Thinning Hair

A NA study of Thinning Hair, sponsored by Ablon Skin Institute Research Center.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06571799 is a NA study of Thinning Hair that has completed, run by Ablon Skin Institute Research Center. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06571799, a NA study of Thinning Hair, has completed, sponsored by Ablon Skin Institute Research Center.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to further substantiate the effectiveness and safety of BENEV Exosome Regenerative Complex+ post SylFirmX® RF microneedling procedure for self-perceived thinning hair in healthy men and women ages 18-65 over the course of four months. Participants will be asked to have treatments monthly for 4 sessions, attend a follow up appointment 4 weeks after the 4th session, have photos taken of their hair and answer questionnaires related to their thinning hair.

Conditions Studied

Interventions

  • OTHER BENEV Exosome Regenerative Complex+

Study Locations (1)

California

  • Ablon Skin Institute & Research Center - Manhattan Beach

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-09-03
Est. Completion 2025-03-27
Phase NA

What the Registry Record Tells You About NCT06571799

The ClinicalTrials.gov registry entry for NCT06571799 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablon Skin Institute Research Center, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thinning Hair appearing as the primary indexed condition, and to 1 intervention - of which BENEV Exosome Regenerative Complex+ is the first listed.

NCT06571799 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06571799 about?

NCT06571799 is a clinical study titled "Study Evaluating the Efficacy and Safety of BENEV Exosome Regenerative Complex+ for Self-perceived Thinning Hair". The goal of this clinical trial is to further substantiate the effectiveness and safety of BENEV Exosome Regenerative Complex+ post SylFirmX® RF microneedling procedure for self-perceived thinning hair in healthy men and women ages 18-65 over the course of four months. Participants will be asked to ...

What is the current status of trial NCT06571799?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-03. Estimated completion is 2025-03-27.

What conditions does trial NCT06571799 study?

This clinical trial studies the following conditions: Thinning Hair.

What interventions are being tested in trial NCT06571799?

The interventions under investigation include: BENEV Exosome Regenerative Complex+ (OTHER).

Who is sponsoring clinical trial NCT06571799?

This trial is sponsored by Ablon Skin Institute Research Center, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06571799 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.